Sikander Ailawadhi, MD, spotlights the characteristics of multiple myeloma that drive the decision to use teclistamab-cqyv, elranatamab-bcmm, or talquetamab-tgvs.
Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.